Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Antiparkinsonian

or Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism)

Use the filters below to narrow your results.

None (1) · Amantadine (1) · Apomorphine (1) · Benztropine (1) · Biperiden (1) · Bromocriptine (1) · Butorphanol (1) · Cabergoline (1) · Carbidopa/levodopa (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Entacapone (1) · Ethylmorphine (1) · Fentanyl (1) · Hydrocodone (1) · Hydromorphone (1) · Levodopa (1) · Levorphanol (1) · Meperidine (1) · Nalbuphine (1) · Opicapone (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Rasagiline (1) · Rotigotine (1) · Safinamide (1) · Selegiline (1) · Tapentadol (1) · Tolcapone (1) · Trihexyphenidyl (1)

None (6) · (multiple, generic dominant) (1) · Akineton (1) · Apokyn (1) · Artane (1) · Azilect (1) · Cogentin (1) · Comtan (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dostinex (1) · Duragesic (1) · Eldepryl (1) · Neupro (1) · Nubain (1) · Nucynta (1) · Nuplazid (1) · Ongentys (1) · Opana (1) · Parlodel (1) · Sinemet (1) · Stadol (1) · Symmetrel (1) · Talwin (1) · Tasmar (1) · Vicodin (1) · Xadago (1)

Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Irreversible selective MAO-B inhibitor (2) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) · Selective M1 muscarinic antagonist (1)

None (31) · Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (31) · 34 mg PO once daily (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (31) · 10 mg, 34 mg capsules/tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (31) · 34 mg/d (1) · 360 mg/day (1)

None (31) · Oral (1) · PO (only formulation marketed in the US). (1)

None (31) · 30–60 min (PO) (1) · Benefit over weeks of dosing (1)

None (31) · 4–6 hours (1) · Daily dosing (1)

None (31) · 2.5–3 hours (1) · ~57 hours (parent), ~200 h (active metabolite) (1)

None (31) · Not characterized; oral dosing once daily (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (31) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data; avoid (1)

None (31) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)